Clinical-stage biotech (Belgium, 2020) developing therapeutics based on optimized consortia of live bacteria.
Disruptive technology for consortia optimization and manufacturing, overcoming key hurdles in field.
Best-in-class therapeutics for inflammatory, CNS and metabolic diseases, excellent safety and disease-modifying potential.
Clinical program in Inflammatory Bowel Diseases (IBD). Preclinical programs in CNS (Parkinson’s Disease, Metabolic diseases (2 programs) and auto-immune diseases (Spondyloarthritis).
MRM Health is based in a Center of Expertise for microbiome research and development in the biotech cluster in Ghent and has a strategic partnership with the VIB, with top research groups in both microbiome analysis and ecology and in host biology and disease research.Corporate Video
MRM Health has a corporate collaboration with IFF (formerly DuPont Nutrition Biosciences) in the discovery and development of microbiome-based therapeutics in the field of metabolic diseases. Other therapeutic areas are available for partnering. The Company is strategically supported by strong local and international investors, including Ackermans & van Haaren, IFF, OMX Venture Fund Europe, Qbic II and VIB.
With its impressive consortia optimization and manufacturing technology, MRM Health disrupts exactly there where others stumble.
Prof. Jeroen Raes, KOL Gut Microbiome VIB-KULeuven, Belgium
MRM Health features End-to-End development capabilities, from discovery to CMC, regulatory and clinical development. We have direct access to the most advanced simulator of the human gut, the Simulator of the Human Intestinal Microbial Ecosystem (SHIME®). In addition, through strategic partnerships with international research centers, MRM Health has secured extensive complementary microbiome and bioinformatics capabilities, multidisciplinary knowhow and patient insights.
Through its proprietary technology platform, MRM Health develops Optimized Consortia, a novel class of microbial therapeutics which surpass the current microbiome approaches. Using a bioinformatics-guided in-human discovery engine, key therapeutic strains are identified and integrated into Optimized Consortia through its proprietary Microbiome Optimization Technology. The Company’s breakthrough GMP-compliant manufacturing technology allows to manufacture therapeutic consortia as a single Drug Substance.
VIB is an excellence-based entrepreneurial research institute in life sciences that focuses on translating basic scientific results into pharmaceutical, agricultural and industrial applications. VIB works in close partnership with Flemish universities, including KU Leuven and Ghent University.